Published in Am J Gastroenterol on April 01, 1990
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci (2007) 2.08
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer (2008) 1.61
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Current management of pancreatic carcinoma. Ann Surg (1995) 1.54
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci (2013) 1.43
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci (2011) 1.30
Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res (2010) 1.29
Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer (1998) 1.28
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med (2013) 1.21
DNA methylation as a universal biomarker. Expert Rev Mol Diagn (2010) 1.18
Obstructive jaundice due to hepatobiliary cystadenoma or cystadenocarcinoma. World J Gastroenterol (2006) 1.16
Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol (2011) 1.13
Pancreatic cancer and the FAMMM syndrome. Fam Cancer (2007) 1.13
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford) (2007) 1.11
Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics (2013) 1.10
Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia (2004) 1.08
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol (2014) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer. J Korean Med Sci (2007) 1.00
Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res (2014) 1.00
Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics (2012) 0.98
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics (2012) 0.96
PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer (2012) 0.95
Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One (2011) 0.95
Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J Surg (2003) 0.94
Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas (2010) 0.92
A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer (2011) 0.92
Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg (2008) 0.91
Increasing the sensitivity of enzyme-linked immunosorbent assay using multiplexed electrokinetic concentrator. Anal Chem (2010) 0.89
Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer (2014) 0.87
Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int J Clin Exp Med (2014) 0.87
Biliary tract obstruction in chronic pancreatitis. HPB (Oxford) (2007) 0.87
Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res (2015) 0.87
CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol (2013) 0.86
Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets (2012) 0.86
Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) (2010) 0.86
Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel) (2010) 0.86
Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection. World J Gastroenterol (2009) 0.86
Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol (2008) 0.85
Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol (2012) 0.85
Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol (2012) 0.84
Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. J Biomed Biotechnol (2010) 0.84
Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol (2013) 0.83
Abnormally high level of CA-19-9 in a benign ovarian cyst. Obstet Gynecol Sci (2015) 0.83
Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J (2009) 0.83
Unusually High Levels of CA19-9 Associated with Mature Cystic Teratoma of the Ovary. Case Rep Obstet Gynecol (2014) 0.83
Autoimmune pancreatitis misdiagnosed as a tumor of the head of the pancreas. World J Gastrointest Surg (2012) 0.83
Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int (2013) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Cholangiocarcinoma: has there been any progress? Can J Gastroenterol (2010) 0.82
Gallbladder mass with a carbohydrate antigen 19-9 level in the thousands: malignant or benign pathology? Report of a case. Surg Today (2007) 0.82
Hepatic inflammatory pseudotumor with elevated serum CA19-9 level mimicking liver metastasis from rectal cancer: report of a case. Int Surg (2013) 0.82
Surgery for pancreatic carcinoma: state of the art. Indian J Surg (2011) 0.81
Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling. BMC Clin Pathol (2014) 0.81
Chronic pancreatitis and pancreatic carcinoma. Postgrad Med J (1997) 0.80
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther (2016) 0.79
Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget (2016) 0.79
Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma. PLoS One (2014) 0.79
Predictors of malignancy in chronic calcific pancreatitis with head mass. World J Gastrointest Surg (2013) 0.79
Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int (2016) 0.79
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One (2015) 0.78
Mirizzi's syndrome masquerading as cholangiocarcinoma: a case report. J Med Case Rep (2012) 0.78
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget (2016) 0.78
Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma. Dig Dis Sci (2014) 0.78
Detection of benign hilar bile duct stenoses - A retrospective analysis in 250 patients with suspicion of Klatskin tumour. Ann Med Surg (Lond) (2016) 0.78
Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels. Afr Health Sci (2015) 0.78
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS One (2016) 0.77
Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures. Dig Dis Sci (2014) 0.77
Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Cancer Biomark (2012) 0.77
Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer. Radiat Oncol J (2016) 0.77
Tumor marker requests in a general teaching Turkish hospital. Indian J Clin Biochem (2007) 0.76
Imaging of focal autoimmune pancreatitis and differentiating it from pancreatic cancer. ISRN Radiol (2013) 0.76
Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer. Clujul Med (2016) 0.75
Non-Invasive Detection of Esophageal Cancer using Genetic Changes in Circulating Cell-Free DNA. Avicenna J Med Biotechnol (2012) 0.75
Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Int J Mol Sci (2017) 0.75
Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. Br J Cancer (2016) 0.75
Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget (2016) 0.75
Pancreatic mucinous cystadenoma with serum CA 19-9 over 1,000,000 U/mL: a case report and review of the literature. World J Surg Oncol (2015) 0.75
Chronic bronchitis with fungal infection presenting with marked elevation of serum carbohydrate antigen 19-9: a case report. Int J Clin Exp Pathol (2014) 0.75
Pancreatic Tuberculosis with Markedly Elevated CA 19-9 Levels: A Diagnostic Pitfall. Oman Med J (2016) 0.75
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol (2016) 0.75
Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Rep Gastroenterol (2016) 0.75
Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol (2012) 0.75
Increased expression of proliferating cell nuclear antigen in autoimmune hepatitis in a patient with raised serum concentration of CA19-9. J Clin Pathol (1998) 0.75
Optical Aptamer Probes of Fluorescent Imaging to Rapid Monitoring of Circulating Tumor Cell. Sensors (Basel) (2016) 0.75
Pancreatic Cancer and Gastroenterology: A Review. Gastroenterology Res (2013) 0.75
Serum CA19-9 in patients with solid pancreatic mass. Gastroenterol Hepatol Bed Bench (2013) 0.75
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer (2017) 0.75
Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver (2017) 0.75